FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington D.C. 20549

wasnington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	ourden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  YAU YI CHING  (Last) (First) (Middle)						Issuer Name and Ticker or Trading Symbol     BridgeBio Pharma, Inc. [ BBIO ]      Date of Earliest Transaction (Month/Day/Year)     08/16/2020									ck all appli Director Officer below)	ationship of Reporting call applicable) Director Officer (give title below) Chief Accou		10% Ov Other (s below)	/ner
C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET								t, Date (	of Original	Filed	i (Month/D	Day/Year)		6. Inc	dividual or			g (Check Ap	pplicable
(Street) PALO A	LTO C.	A :	94301										X	Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date			2. Transa Date (Month/D	ay/Year)   Execut		A. Deemed execution Date, any Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			5. Amou Securiti Benefici Owned	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) (D)	or P	rice	Transac (Instr. 3	ction(s)			(
Common Stock 08			08/16	/2020	2020			М		398	A		(1)	1,131(2)			D		
Common Stock 08/16/				/2020	2020		F		138(3)		\$	28.53	993			D			
		Т	able II -								osed of converti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,		Transaction Code (Instr.		of I		6. Date Exercisabl Expiration Date (Month/Day/Year)		Amount of		urity	. Price of Perivative Pecurity Pecurity Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owner Form: Direct or Indi (I) (Ins	Ownership	Beneficial Ownership (Instr. 4)
					Code	v	(A)		Date Exercisab		Expiration Date	Title	or Nur of	ount mber ares					
Restricted Stock Units	(1)	08/16/2020			M			398	(4)	T	(4)	Common Stock	3	98	\$0.00	5,985		D	

## Explanation of Responses:

- 1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- 2. Includes 733 shares acquired by the Reporting Person on August 14, 2020 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
- 3. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 398 shares of Common Stock underlying the Reporting Person's Restricted Stock Units.
- 4. The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.

## Remarks:

/s/ Tara Condon, Attorney-in-

<u>Fact</u>

08/18/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.